New hope for tough blood cancers: CBX-250 trial opens
NCT ID NCT06994676
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug called CBX-250 in about 72 people with certain blood cancers (like acute myeloid leukemia) that have returned or not improved with standard therapy. The main goals are to check the drug's safety and find the best dose. Participants receive CBX-250 as a shot under the skin in 28-day cycles and continue until their disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
-
Northwestern Medicine
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sarah Cannon Cancer Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-••••
-
Stanford Medical Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Email: •••••@•••••
Contact
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.